Heart failure therapy-induced early ST2 changes may offer long-term therapy guidance

Journal of Cardiac Failure

Volumn 19, Issue 12, 2013, Pages 821-828

  Breidthardt, Tobias ^a   Balmelli, Cathrin ^a   Twerenbold, Raphael ^a   Mosimann, Tamina ^a   Espinola, Jaqueline ^b   Haaf, Philip ^a   Thalmann, Gregor ^a   Moehring, Berit ^a   Mueller, Mira ^a   Meller, Bernadette ^a   Reichlin, Tobias ^a   Murray, Karsten ^a   Ziller, Ronny ^a   Benkert, Pascal ^c   Osswald, Stefan ^a   Mueller, Christian ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Acute heart failure; heart failure therapy; mortality; ST2

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; DIURETIC AGENT; INTERLEUKIN 1 RECEPTOR; SOLUBLE RECEPTOR ST2; UNCLASSIFIED DRUG;

AGED; ARTICLE; CARCINOGENICITY; CREATININE BLOOD LEVEL; DIURETIC THERAPY; ECHOCARDIOGRAPHY; EMERGENCY WARD; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEALTH STATUS; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART RATE; HEMOGLOBIN BLOOD LEVEL; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; HYPERVOLEMIA; LEUKOCYTE COUNT; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; SHORT TERM SURVIVAL; SURVIVAL RATE; SURVIVOR; SYSTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE MARKER; INFLAMMATION; SURVIVAL; VERY ELDERLY;

ACUTE HEART FAILURE; HEART FAILURE THERAPY; MORTALITY; ST2;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; COHORT STUDIES; EARLY DIAGNOSIS; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; MALE; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; RECEPTORS, CELL SURFACE; TIME FACTORS;

EID: 84890253068     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2013.11.003     Document Type: Article

References (41)

1. L. de Luca, G.C. Fonarow, and K.F. Adams Jr. Acute heart failure syndromes: clinical scenarios and pathophysiologic targets for therapy Heart Fail Rev 12 2007 97 104
2. K.F. Adams Jr., G.C. Fonarow, and C.L. Emerman Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE) Am Heart J 149 2005 209 216
3. C.Y. Wong, S.I. Chaudhry, M.M. Desai, and H.M. Krumholz Trends in comorbidity, disability, and polypharmacy in heart failure Am J Med 124 2011 136 143
4. J.L. Fleg, W.S. Aronow, and W.H. Frishman Cardiovascular drug therapy in the elderly: benefits and challenges Nat Rev Cardiol 8 2011 13 28
5. M. Noveanu, T. Breidthardt, and M. Potocki Direct comparison of serial B-type natriuretic peptide and NT-proBNP levels for prediction of short- and long-term outcome in acute decompensated heart failure Crit Care 15 2011 R1
6. M. O'Donoghue, and E. Braunwald Natriuretic peptides in heart failure: should therapy be guided by BNP levels? Nat Rev Cardiol 7 2010 13 20
7. P. Porapakkham, H. Zimmet, B. Billah, and H. Krum B-Type natriuretic peptide-guided heart failure therapy: a meta-analysis Arch Intern Med 170 2010 507 514
8. T. Breidthardt, G. Vanpoucke, and M. Potocki The novel marker LTBP2 predicts all-cause and pulmonary death in patients with acute dyspnoea Clin Sci (Lond) 123 2012 557 566
9. I. Manabe, T. Shindo, and R. Nagai Gene expression in fibroblasts and fibrosis: involvement in cardiac hypertrophy Circ Res 91 2002 1103 1113
10. R. Kakkar, and R.T. Lee The IL-33/ST2 pathway: therapeutic target and novel biomarker Nat Rev Drug Discov 7 2008 827 840
11. H. Uthoff, C. Thalhammer, and M. Potocki Central venous pressure at emergency room presentation predicts cardiac rehospitalization in patients with decompensated heart failure Eur J Heart Fail 12 2010 469 476
12. B. Mayer, S.R. Holmer, C. Hengstenberg, W. Lieb, M. Pfeifer, and H. Schunkert Functional improvement in heart failure patients treated with beta-blockers is associated with a decline of cytokine levels Int J Cardiol 103 2005 182 186
13. M. Nishio, Y. Sakata, and T. Mano Beneficial effects of bisoprolol on the survival of hypertensive diastolic heart failure model rats Eur J Heart Fail 10 2008 446 453
14. L. Rossig, J. Haendeler, and Z. Mallat Congestive heart failure induces endothelial cell apoptosis: protective role of carvedilol J Am Coll Cardiol 36 2000 2081 2089
15. T. Socrates, C. deFilippi, and T. Reichlin Interleukin family member ST2 and mortality in acute dyspnoea J Intern Med 268 2010 493 500
16. B. Dieplinger, J.L. Januzzi Jr., and M. Steinmair Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma - the Presage ST2 assay Clin Chim Acta 409 2009 33 40
17. A.H. Wu, F. Wians, and A. Jaffe Biological variation of galectin-3 and soluble ST2 for chronic heart failure: implication on interpretation of test results Am Heart J 165 2013 995 999
18. G.C. Fonarow, K.F. Adams Jr., W.T. Abraham, C.W. Yancy, and W.J. Boscardin Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis JAMA 293 2005 572 580
19. E.R. DeLong, D.M. DeLong, and D.L. Clarke-Pearson Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach Biometrics 44 1988 837 845
20. M.J. Pencina, R.B. d'Agostino Sr., R.B. d'Agostino Jr., and R.S. Vasan Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond Statistics in medicine 27 2008 157 172 discussion 207-12
21. J.L. Januzzi Jr., W.F. Peacock, and A.S. Maisel Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study J Am Coll Cardiol 50 2007 607 613
22. T. Mueller, B. Dieplinger, A. Gegenhuber, W. Poelz, R. Pacher, and M. Haltmayer Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure Clin Chem 54 2008 752 756
23. S. Boisot, J. Beede, and S. Isakson Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure J Card Fail 14 2008 732 738
24. Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial Lancet 353 1999 9 13
25. M. Packer, A.J. Coats, and M.B. Fowler Effect of carvedilol on survival in severe chronic heart failure N Engl J Med 344 2001 1651 1658
26. CONSENSUS Trial Study Group Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS) N Engl J Med 316 1987 1429 1435
27. SOLVD Investigators Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure N Engl J Med 325 1991 293 302
28. Z.J. Eapen, S.D. Reed, and Y. Li Do countries or hospitals with longer hospital stays for acute heart failure have lower readmission rates? Findings from ASCEND-HF Circ Heart Fail 6 2013 727 732
29. W.F. Peacock, M.R. Costanzo, and T. De Marco Impact of intravenous loop diuretics on outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE registry Cardiology 113 2009 12 19
30. A. Ahmed, A. Husain, and T.E. Love Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods Eur Heart J 27 2006 1431 1439
31. E.F. Philbin, M. Cotto, T.A. Rocco Jr., and P.L. Jenkins Association between diuretic use, clinical response, and death in acute heart failure Am J Cardiol 80 1997 519 522
32. G.W. Neuberg, A.B. Miller, and C.M. O'Connor Diuretic resistance predicts mortality in patients with advanced heart failure Am Heart J 144 2002 31 38
33. J. Schmitz, A. Owyang, and E. Oldham IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines Immunity 23 2005 479 490
34. E.K. Brint, D. Xu, and H. Liu ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance Nat Immunol 5 2004 373 379
35. S. Sanada, D. Hakuno, L.J. Higgins, E.R. Schreiter, A.N. McKenzie, and R.T. Lee IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system J Clin Invest 117 2007 1538 1549
36. K. Seki, S. Sanada, and A.Y. Kudinova Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling Circ Heart Fail 2 2009 684 691
37. H. Hayakawa, M. Hayakawa, A. Kume, and S. Tominaga Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation J Biol Chem 282 2007 26369 26380
38. M. Shimpo, D.A. Morrow, and E.O. Weinberg Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction Circulation 109 2004 2186 2190
39. M.S. Nieminen, D. Brutsaert, and K. Dickstein EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population Eur Heart J 27 2006 2725 2736
40. J.T. Heywood, G.C. Fonarow, M.R. Costanzo, V.S. Mathur, J.R. Wigneswaran, and J. Wynne High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database J Card Fail 13 2007 422 430
41. C.M. O'Connor, W.G. Stough, D.S. Gallup, V. Hasselblad, and M. Gheorghiade Demographics, clinical characteristics, and outcomes of patients hospitalized for decompensated heart failure: observations from the IMPACT-HF Registry J Card Fail 11 2005 200 205